CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

How Biotech Startups can Mitigate...

Vivid Microscopy Detects Early Stages of Heart Disease Using an Animal Model

Vivid Microscopy Detects Early Stages...

How Contract Manufacturing Benefitting Small Businesses

How Contract Manufacturing...

Top Biotech Industry Trends to Watch for in 2022

Top Biotech Industry Trends to Watch...

European Life Sciences Off to a New Beginning

European Life Sciences Off to a New...

Encore Healthcare's VP of Clinical Operations Carrie Hylton-Proffitt, RRT Earns Accreditation with ACHC

Encore Healthcare's VP of Clinical...

How are Advancements in Biotechnology Help People Improve their Lives?

How are Advancements in Biotechnology...

Key Trends in Bioengineering to Watch for in 2022

Key Trends in Bioengineering to Watch...

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

How Biotech Startups can Mitigate...

Vivid Microscopy Detects Early Stages of Heart Disease Using an Animal Model

Vivid Microscopy Detects Early Stages...

How Contract Manufacturing Benefitting Small Businesses

How Contract Manufacturing...

Top Biotech Industry Trends to Watch for in 2022

Top Biotech Industry Trends to Watch...

European Life Sciences Off to a New Beginning

European Life Sciences Off to a New...

Encore Healthcare's VP of Clinical Operations Carrie Hylton-Proffitt, RRT Earns Accreditation with ACHC

Encore Healthcare's VP of Clinical...

How are Advancements in Biotechnology Help People Improve their Lives?

How are Advancements in Biotechnology...

Key Trends in Bioengineering to Watch for in 2022

Key Trends in Bioengineering to Watch...

Challenges Facing Biotech Companies Seeking Funding

Life Sciences Review | Monday, January 03, 2022
Tweet

Early-stage biotech companies have a smaller audience of institutional investors than companies with more traditional business models due to their complex nature, long path to profitability, and a significant degree of clinical, regulatory, and commercial risk.


Fremont, CA: Over the last two decades, the biotech market has grown rapidly and is expected to be worth nearly $2.5 trillion by 2028. Meanwhile, the rate of technological advancement and innovation has lowered entry barriers, resulting in a flood of aspiring biotech startups eager to bring their products to market. Despite an increase in available capital, early-stage biotech companies are having a more difficult time getting their fair share of funding. We will look at the challenges, strategies, and best practices in early-stage biotech funding in this article.


Challenges facing biotech companies seeking funding:


Securing Early-stage Investment


Biotech startups need to become a "core" position – a significant holding that is held long term – for at least a few established buy-side investors in order to build a solid investor base. 


On the other hand, core positions are typically established through structured biotech financings such as follow-on offerings, IPOs, and, more recently, late-stage private crossover financing rounds. And, because most funds have a limited number of core positions, the only way for a new core holding to become available is to sell another.


Despite the fact that investors' portfolios are growing in size, capital is being deployed into existing positions rather than new, large investments. As the number of early-stage biotech companies grows in comparison to a fixed number of core positions, the demand for funding outstrips the supply of available core positions. Management teams should find alternative funding sources to support the company long-term in order to secure the early-stage investment that will propel it forward.


Narrow Audience


Early-stage biotech companies have a smaller audience of institutional investors than companies with more traditional business models due to their complex nature, long path to profitability, and a significant degree of clinical, regulatory, and commercial risk. Beyond the traditional life science dedicated funds, few generalist fund managers consider smaller cap life science companies unless they have a growth strategy with high-risk tolerance as well as longer time horizons to hold positions through maturity.


Weekly Brief

loading
Top 10 Biotech Startups Companies - 2022
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/challenges-facing-biotech-companies-seeking-funding-nwid-683.html